ScripMerus is striking while the iron is hot after presenting impressive Phase II results from its head and neck cancer candidate, petosemtamab, raising about $300m in a public share offering to fund the d
ScripMerus’ petosemtamab is now tipped to be a future standard of care in PD-L1 positive head and neck cancer after updated Phase II results showed that it clearly improved response rates and overall survi
In VivoWhen Hans Clevers took the helm of Pharma Research and Early Development (pRED) at Roche, he faced a unique challenge: scaling the leadership principles he had developed running a 35-person academic l
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis